A process for the synthesis of lactams suitable for use in antimicrobial, anti-biofilm and bacteriostatic compositions.

The invention relates to compositions and methods for inhibiting Krüppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.

The invention relates to compositions and methods for inhibiting Krüppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.

The invention relates to a modified textile comprising a) a textile substrate; and, b) a lactam coating; and to the use of a lactam to impart anti-biofilm properties to a textile; and to the use of a lactam to inhibit biofilm growth on a textile substrate; wherein the lactam is selected from: (I) 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one; and (II) 5-methylene-4-(p-tolyl)pyrrol-2-one; (III) 4-(4-bromophenyl)-5-methylene-pyrrol-2-one; (IV) 4-(3-chlorophenyl)-5-methylene-pyrrol-2-one; (V) 4-(2-fluorophenyl)-5-methylene-pyrrol-2-one; and (VI).

##STR00001##

The invention relates to a modified textile comprising a) a textile substrate; and, b) a lactam coating; and to the use of a lactam to impart anti-biofilm properties to a textile; and to the use of a lactam to inhibit biofilm growth on a textile substrate; wherein the lactam is selected from: (I) 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one; and (II) 5-methylene-4-(p-tolyl)pyrrol-2-one; (III) 4-(4-bromophenyl)-5-methylene-pyrrol-2-one; (IV) 4-(3-chlorophenyl)-5-methylene-pyrrol-2-one; (V) 4-(2-fluorophenyl)-5-methylene-pyrrol-2-one; and (VI).

##STR00001##

The invention relates to a wipe suitable for application to a hard surface comprising from 0.0001 to 5 wt. % of a lactam; to the use of said wipe on a surface to reduce microorganism buildup on said surface; and, to the use of a lactam in a wipe product to enhance preservation of said wipe product.

A method of preparing bilirubin IXα from biliverdin IXα diester, the method including: 1) adding sodium hydroxide dissolved in a first methanol solution to biliverdin IXα diester dissolved in a second methanol solution, to yield a first mixture; adding water to the first mixture to hydrolyze biliverdin IXα diester; adding an acid to the first mixture to adjust the pH value thereof; removing a first solvent of the first mixture through rotary evaporation, and removing an inorganic salt through rinsing, and vacuum drying, to yield biliverdin IXα; and 2) dissolving the biliverdin IXα in an alcoholic solution, and adding a radical scavenger and borohydride to the alcoholic solution, to yield a second mixture; adding a ketone to the second mixture to decompose excess borohydride; adding the acid to the second mixture to adjust the pH value thereof; and removing a second solvent of the second mixture through rotary evaporation.

A method of preparing bilirubin IXα from biliverdin IXα diester, the method including: 1) adding sodium hydroxide dissolved in a first methanol solution to biliverdin IXα diester dissolved in a second methanol solution, to yield a first mixture; adding water to the first mixture to hydrolyze biliverdin IXα diester; adding an acid to the first mixture to adjust the pH value thereof; removing a first solvent of the first mixture through rotary evaporation, and removing an inorganic salt through rinsing, and vacuum drying, to yield biliverdin IXα; and 2) dissolving the biliverdin IXα in an alcoholic solution, and adding a radical scavenger and borohydride to the alcoholic solution, to yield a second mixture; adding a ketone to the second mixture to decompose excess borohydride; adding the acid to the second mixture to adjust the pH value thereof; and removing a second solvent of the second mixture through rotary evaporation.

The present disclosure describes novel compounds and compositions that reduce nicotine mediated cravings in humans. In embodiments, the novel compounds blocking CYP2A6-meditated nicotine metabolism thereby reducing the need for additional nicotine. Leading to a desirable treatment option in reducing nicotine craving which does not exacerbate the sympathetic response rate caused by the abused substance and which has favorable pharmacodynamics effects.

The present disclosure describes novel compounds and compositions that reduce nicotine mediated cravings in humans. In embodiments, the novel compounds blocking CYP2A6-meditated nicotine metabolism thereby reducing the need for additional nicotine. Leading to a desirable treatment option in reducing nicotine craving which does not exacerbate the sympathetic response rate caused by the abused substance and which has favorable pharmacodynamics effects.